牛唐2021-03-31 09:44
$灿菲特生物制药(CANF)$ 的药物Piclidenoson和Namodenoson在现有的六份分销协议中,剩余的潜在里程碑付款高达约1.3亿美元,外加两位数的净销售额分成。$新泰医药(MDGL)$ $泰格医药(SZ300347)$查看全文
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001013762-24-001791 Act: 34 Size: 22 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-060625 Act: 34 Size: 24 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-058931 Act: 34 Size: 10 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-057535 Act: 34 Size: 42 KB 网页链接
$Can-fite Biopharma(CANF)$ 424B7 Prospectus [Rule 424(b)(7)] Accession Number: 0001213900-24-057194 Act: 33 Size: 42 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-056848 Act: 34 Size: 25 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-056177 Act: 34 Size: 9 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-054980 Act: 34 Size: 22 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-050960 Act: 34 Size: 26 KB 网页链接
$Can-fite Biopharma(CANF)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001213900-24-050777 Act: 34 Size: 1 MB 网页链接